Clinical practice with anti-dementia drugs

A revised (third) consensus statement from the British Association for Psychopharmacology

John T. O'Brien, Clive Holmes, Matthew Jones, Roy Jones, Gill Livingston, Ian McKeith, Peter Mittler, Peter Passmore, Craig Ritchie, Louise Robinson, Elizabeth L. Sampson, John Paul Taylor, Alan Thomas, Alistair Burns

Research output: Contribution to journalReview article

50 Citations (Scopus)

Abstract

The British Association for Psychopharmacology coordinated a meeting of experts to review and revise its previous 2011 guidelines for clinical practice with anti-dementia drugs. As before, levels of evidence were rated using accepted standards which were then translated into grades of recommendation A-D, with A having the strongest evidence base (from randomised controlled trials) and D the weakest (case studies or expert opinion). Current clinical diagnostic criteria for dementia have sufficient accuracy to be applied in clinical practice (B) and both structural (computed tomography and magnetic resonance imaging) and functional (positron emission tomography and single photon emission computerised tomography) brain imaging can improve diagnostic accuracy in particular situations (B). Cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) are effective for cognition in mild to moderate Alzheimer's disease (A), memantine for moderate to severe Alzheimer's disease (A) and combination therapy (cholinesterase inhibitors and memantine) may be beneficial (B). Drugs should not be stopped just because dementia severity increases (A). Until further evidence is available other drugs, including statins, anti-inflammatory drugs, vitamin E, nutritional supplements and Ginkgo biloba, cannot be recommended either for the treatment or prevention of Alzheimer's disease (A). Neither cholinesterase inhibitors nor memantine are effective in those with mild cognitive impairment (A). Cholinesterase inhibitors are not effective in frontotemporal dementia and may cause agitation (A), though selective serotonin reuptake inhibitors may help behavioural (but not cognitive) features (B). Cholinesterase inhibitors should be used for the treatment of people with Lewy body dementias (both Parkinson's disease dementia and dementia with Lewy bodies), and memantine may be helpful (A). No drugs are clearly effective in vascular dementia, though cholinesterase inhibitors are beneficial in mixed dementia (B). Early evidence suggests multifactorial interventions may have potential to prevent or delay the onset of dementia (B). Though the consensus statement focuses on medication, psychological interventions can be effective in addition to pharmacotherapy, both for cognitive and non-cognitive symptoms. Many novel pharmacological approaches involving strategies to reduce amyloid and/or tau deposition in those with or at high risk of Alzheimer's disease are in progress. Though results of pivotal studies in early (prodromal/mild) Alzheimer's disease are awaited, results to date in more established (mild to moderate) Alzheimer's disease have been equivocal and no disease modifying agents are either licensed or can be currently recommended for clinical use.

Original languageEnglish
Pages (from-to)147-168
Number of pages22
JournalJournal of Psychopharmacology
Volume31
Issue number2
Early online date20 Jan 2017
DOIs
Publication statusPublished - 1 Feb 2017

Fingerprint

Cholinesterase Inhibitors
Memantine
Dementia
Consensus
Alzheimer Disease
Pharmaceutical Preparations
Lewy Body Disease
Rivastigmine
Galantamine
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Ginkgo biloba
Frontotemporal Dementia
Vascular Dementia
Serotonin Uptake Inhibitors
Expert Testimony
Single-Photon Emission-Computed Tomography
Vitamin E
Practice Guidelines
Amyloid
Neuroimaging

Keywords

  • Alzheimer's disease
  • Dementia
  • frontotemporal
  • guidelines
  • Lewy
  • management
  • treatment
  • vascular

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Clinical practice with anti-dementia drugs : A revised (third) consensus statement from the British Association for Psychopharmacology. / O'Brien, John T.; Holmes, Clive; Jones, Matthew; Jones, Roy; Livingston, Gill; McKeith, Ian; Mittler, Peter; Passmore, Peter; Ritchie, Craig; Robinson, Louise; Sampson, Elizabeth L.; Taylor, John Paul; Thomas, Alan; Burns, Alistair.

In: Journal of Psychopharmacology, Vol. 31, No. 2, 01.02.2017, p. 147-168.

Research output: Contribution to journalReview article

O'Brien, JT, Holmes, C, Jones, M, Jones, R, Livingston, G, McKeith, I, Mittler, P, Passmore, P, Ritchie, C, Robinson, L, Sampson, EL, Taylor, JP, Thomas, A & Burns, A 2017, 'Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology', Journal of Psychopharmacology, vol. 31, no. 2, pp. 147-168. https://doi.org/10.1177/0269881116680924
O'Brien, John T. ; Holmes, Clive ; Jones, Matthew ; Jones, Roy ; Livingston, Gill ; McKeith, Ian ; Mittler, Peter ; Passmore, Peter ; Ritchie, Craig ; Robinson, Louise ; Sampson, Elizabeth L. ; Taylor, John Paul ; Thomas, Alan ; Burns, Alistair. / Clinical practice with anti-dementia drugs : A revised (third) consensus statement from the British Association for Psychopharmacology. In: Journal of Psychopharmacology. 2017 ; Vol. 31, No. 2. pp. 147-168.
@article{a3bd976baa7048adbd7c1cb616082dcd,
title = "Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology",
abstract = "The British Association for Psychopharmacology coordinated a meeting of experts to review and revise its previous 2011 guidelines for clinical practice with anti-dementia drugs. As before, levels of evidence were rated using accepted standards which were then translated into grades of recommendation A-D, with A having the strongest evidence base (from randomised controlled trials) and D the weakest (case studies or expert opinion). Current clinical diagnostic criteria for dementia have sufficient accuracy to be applied in clinical practice (B) and both structural (computed tomography and magnetic resonance imaging) and functional (positron emission tomography and single photon emission computerised tomography) brain imaging can improve diagnostic accuracy in particular situations (B). Cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) are effective for cognition in mild to moderate Alzheimer's disease (A), memantine for moderate to severe Alzheimer's disease (A) and combination therapy (cholinesterase inhibitors and memantine) may be beneficial (B). Drugs should not be stopped just because dementia severity increases (A). Until further evidence is available other drugs, including statins, anti-inflammatory drugs, vitamin E, nutritional supplements and Ginkgo biloba, cannot be recommended either for the treatment or prevention of Alzheimer's disease (A). Neither cholinesterase inhibitors nor memantine are effective in those with mild cognitive impairment (A). Cholinesterase inhibitors are not effective in frontotemporal dementia and may cause agitation (A), though selective serotonin reuptake inhibitors may help behavioural (but not cognitive) features (B). Cholinesterase inhibitors should be used for the treatment of people with Lewy body dementias (both Parkinson's disease dementia and dementia with Lewy bodies), and memantine may be helpful (A). No drugs are clearly effective in vascular dementia, though cholinesterase inhibitors are beneficial in mixed dementia (B). Early evidence suggests multifactorial interventions may have potential to prevent or delay the onset of dementia (B). Though the consensus statement focuses on medication, psychological interventions can be effective in addition to pharmacotherapy, both for cognitive and non-cognitive symptoms. Many novel pharmacological approaches involving strategies to reduce amyloid and/or tau deposition in those with or at high risk of Alzheimer's disease are in progress. Though results of pivotal studies in early (prodromal/mild) Alzheimer's disease are awaited, results to date in more established (mild to moderate) Alzheimer's disease have been equivocal and no disease modifying agents are either licensed or can be currently recommended for clinical use.",
keywords = "Alzheimer's disease, Dementia, frontotemporal, guidelines, Lewy, management, treatment, vascular",
author = "O'Brien, {John T.} and Clive Holmes and Matthew Jones and Roy Jones and Gill Livingston and Ian McKeith and Peter Mittler and Peter Passmore and Craig Ritchie and Louise Robinson and Sampson, {Elizabeth L.} and Taylor, {John Paul} and Alan Thomas and Alistair Burns",
year = "2017",
month = "2",
day = "1",
doi = "10.1177/0269881116680924",
language = "English",
volume = "31",
pages = "147--168",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "Sage Publications",
number = "2",

}

TY - JOUR

T1 - Clinical practice with anti-dementia drugs

T2 - A revised (third) consensus statement from the British Association for Psychopharmacology

AU - O'Brien, John T.

AU - Holmes, Clive

AU - Jones, Matthew

AU - Jones, Roy

AU - Livingston, Gill

AU - McKeith, Ian

AU - Mittler, Peter

AU - Passmore, Peter

AU - Ritchie, Craig

AU - Robinson, Louise

AU - Sampson, Elizabeth L.

AU - Taylor, John Paul

AU - Thomas, Alan

AU - Burns, Alistair

PY - 2017/2/1

Y1 - 2017/2/1

N2 - The British Association for Psychopharmacology coordinated a meeting of experts to review and revise its previous 2011 guidelines for clinical practice with anti-dementia drugs. As before, levels of evidence were rated using accepted standards which were then translated into grades of recommendation A-D, with A having the strongest evidence base (from randomised controlled trials) and D the weakest (case studies or expert opinion). Current clinical diagnostic criteria for dementia have sufficient accuracy to be applied in clinical practice (B) and both structural (computed tomography and magnetic resonance imaging) and functional (positron emission tomography and single photon emission computerised tomography) brain imaging can improve diagnostic accuracy in particular situations (B). Cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) are effective for cognition in mild to moderate Alzheimer's disease (A), memantine for moderate to severe Alzheimer's disease (A) and combination therapy (cholinesterase inhibitors and memantine) may be beneficial (B). Drugs should not be stopped just because dementia severity increases (A). Until further evidence is available other drugs, including statins, anti-inflammatory drugs, vitamin E, nutritional supplements and Ginkgo biloba, cannot be recommended either for the treatment or prevention of Alzheimer's disease (A). Neither cholinesterase inhibitors nor memantine are effective in those with mild cognitive impairment (A). Cholinesterase inhibitors are not effective in frontotemporal dementia and may cause agitation (A), though selective serotonin reuptake inhibitors may help behavioural (but not cognitive) features (B). Cholinesterase inhibitors should be used for the treatment of people with Lewy body dementias (both Parkinson's disease dementia and dementia with Lewy bodies), and memantine may be helpful (A). No drugs are clearly effective in vascular dementia, though cholinesterase inhibitors are beneficial in mixed dementia (B). Early evidence suggests multifactorial interventions may have potential to prevent or delay the onset of dementia (B). Though the consensus statement focuses on medication, psychological interventions can be effective in addition to pharmacotherapy, both for cognitive and non-cognitive symptoms. Many novel pharmacological approaches involving strategies to reduce amyloid and/or tau deposition in those with or at high risk of Alzheimer's disease are in progress. Though results of pivotal studies in early (prodromal/mild) Alzheimer's disease are awaited, results to date in more established (mild to moderate) Alzheimer's disease have been equivocal and no disease modifying agents are either licensed or can be currently recommended for clinical use.

AB - The British Association for Psychopharmacology coordinated a meeting of experts to review and revise its previous 2011 guidelines for clinical practice with anti-dementia drugs. As before, levels of evidence were rated using accepted standards which were then translated into grades of recommendation A-D, with A having the strongest evidence base (from randomised controlled trials) and D the weakest (case studies or expert opinion). Current clinical diagnostic criteria for dementia have sufficient accuracy to be applied in clinical practice (B) and both structural (computed tomography and magnetic resonance imaging) and functional (positron emission tomography and single photon emission computerised tomography) brain imaging can improve diagnostic accuracy in particular situations (B). Cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) are effective for cognition in mild to moderate Alzheimer's disease (A), memantine for moderate to severe Alzheimer's disease (A) and combination therapy (cholinesterase inhibitors and memantine) may be beneficial (B). Drugs should not be stopped just because dementia severity increases (A). Until further evidence is available other drugs, including statins, anti-inflammatory drugs, vitamin E, nutritional supplements and Ginkgo biloba, cannot be recommended either for the treatment or prevention of Alzheimer's disease (A). Neither cholinesterase inhibitors nor memantine are effective in those with mild cognitive impairment (A). Cholinesterase inhibitors are not effective in frontotemporal dementia and may cause agitation (A), though selective serotonin reuptake inhibitors may help behavioural (but not cognitive) features (B). Cholinesterase inhibitors should be used for the treatment of people with Lewy body dementias (both Parkinson's disease dementia and dementia with Lewy bodies), and memantine may be helpful (A). No drugs are clearly effective in vascular dementia, though cholinesterase inhibitors are beneficial in mixed dementia (B). Early evidence suggests multifactorial interventions may have potential to prevent or delay the onset of dementia (B). Though the consensus statement focuses on medication, psychological interventions can be effective in addition to pharmacotherapy, both for cognitive and non-cognitive symptoms. Many novel pharmacological approaches involving strategies to reduce amyloid and/or tau deposition in those with or at high risk of Alzheimer's disease are in progress. Though results of pivotal studies in early (prodromal/mild) Alzheimer's disease are awaited, results to date in more established (mild to moderate) Alzheimer's disease have been equivocal and no disease modifying agents are either licensed or can be currently recommended for clinical use.

KW - Alzheimer's disease

KW - Dementia

KW - frontotemporal

KW - guidelines

KW - Lewy

KW - management

KW - treatment

KW - vascular

UR - http://www.scopus.com/inward/record.url?scp=85011818912&partnerID=8YFLogxK

UR - https://doi.org/10.1177/0269881116680924

U2 - 10.1177/0269881116680924

DO - 10.1177/0269881116680924

M3 - Review article

VL - 31

SP - 147

EP - 168

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

IS - 2

ER -